Drugs / tafetinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02717741 | May 2015 → Apr 2017 | neoplasm | Nanjing Yoko Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tafetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02717741 ↗ |
| Known as | SIM 010603 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2180602 ↗ |
| Action | Inhibit | “inhibits Vascular Endothelial Growth Factor Receptor (VEGFR).” NCT02717741 ↗ |
| Modality | Small molecule | — CHEMBL2180602 ↗ |
| Route | Oral | “Tafetinib is an oral multitargeted tyrosine kinase inhibitor” NCT02717741 ↗ |